Krystal Biotech (NASDAQ:KRYS) Hits New 1-Year High at $218.55

Krystal Biotech, Inc. (NASDAQ:KRYS)’s stock price reached a new 52-week high during trading on Friday . The company traded as high as $218.55 and last traded at $218.14, with a volume of 15172 shares changing hands. The stock had previously closed at $210.69.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on KRYS shares. Stifel Nicolaus reaffirmed a “buy” rating and issued a $204.00 price objective (up previously from $178.00) on shares of Krystal Biotech in a research note on Tuesday, April 16th. HC Wainwright reissued a “buy” rating and set a $200.00 price target on shares of Krystal Biotech in a research report on Monday, May 6th. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $177.63.

Krystal Biotech Trading Up 1.7 %

The firm has a 50-day moving average of $180.54 and a two-hundred day moving average of $160.14. The firm has a market capitalization of $6.12 billion, a PE ratio of 112.67 and a beta of 0.84.

Krystal Biotech (NASDAQ:KRYS) last released its earnings results on Monday, May 6th. The company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.20 by ($0.17). The firm had revenue of $45.25 million during the quarter, compared to the consensus estimate of $47.37 million. The firm’s quarterly revenue was up 452400.0% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.76) EPS. Equities research analysts expect that Krystal Biotech, Inc. will post 2.15 earnings per share for the current fiscal year.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total value of $4,394,000.00. Following the completion of the sale, the insider now directly owns 1,525,882 shares in the company, valued at approximately $268,189,020.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In related news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Tuesday, June 11th. The shares were sold at an average price of $175.76, for a total transaction of $4,394,000.00. Following the sale, the insider now directly owns 1,525,882 shares in the company, valued at approximately $268,189,020.32. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Julian S. Gangolli sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, May 20th. The stock was sold at an average price of $164.13, for a total transaction of $3,282,600.00. The disclosure for this sale can be found here. Corporate insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

A number of large investors have recently modified their holdings of the stock. Jamison Private Wealth Management Inc. bought a new stake in shares of Krystal Biotech in the second quarter worth $28,000. GAMMA Investing LLC lifted its position in shares of Krystal Biotech by 160.3% during the 2nd quarter. GAMMA Investing LLC now owns 151 shares of the company’s stock valued at $28,000 after buying an additional 93 shares in the last quarter. Blue Trust Inc. raised its stake in Krystal Biotech by 2,328.6% during the 2nd quarter. Blue Trust Inc. now owns 170 shares of the company’s stock worth $30,000 after acquiring an additional 163 shares during the period. Quest Partners LLC purchased a new position in Krystal Biotech during the fourth quarter valued at approximately $127,000. Finally, Pier 88 Investment Partners LLC bought a new stake in Krystal Biotech in the fourth quarter worth $145,000. Institutional investors own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).